ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ONT Oxford Nanopore Technologies Plc

136.30
4.10 (3.10%)
Last Updated: 14:51:47
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Nanopore Technologies Plc LSE:ONT London Ordinary Share GB00BP6S8Z30 ORD GBP0.0001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.10 3.10% 136.30 135.50 136.40 139.30 129.90 130.00 1,544,825 14:51:47
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169.67M -154.51M -0.1768 -7.60 1.16B
Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 132.20p. Over the last year, Oxford Nanopore Technolo... shares have traded in a share price range of 86.00p to 275.00p.

Oxford Nanopore Technolo... currently has 873,871,414 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £1.16 billion. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -7.60.

Oxford Nanopore Technolo... Share Discussion Threads

Showing 2976 to 2996 of 3325 messages
Chat Pages: Latest  121  120  119  118  117  116  115  114  113  112  111  110  Older
DateSubjectAuthorDiscuss
04/3/2024
12:03
Limited Anti-Takeover shares.

Gordon, Spike and Clive each held one LAT share just before the flotation.
These enable them to veto a takeover in the event of a 50%+ cohort of all other shareholders approving one at a general meeting held for such an event.

This is/was designed to prevent a cheap takeout before the tech had a chance to mature.

This policy has failed, as to be genuinely effective it should not have expired until 2026, when the co. is forecast to reach profitability and become financially self reliant. It has emboldened shorts, and kept the share out of UKX trackers, and other funds.

bamboo2
04/3/2024
11:18
Bamboo - please explain acronym - LAT share?
brucie5
04/3/2024
10:30
Reading between the lines, the directorate changes last week indicate to me that there is no intention of prolonging the life of the LAT shares held by Gordon, Spike and Clive, after they expire in June 2024. Clive is ahead of the game and has given up his veto already.

This means that ONT is then entitled to join the UKX, other indices, and qualifies for addition to funds that exclude shares in companies with anti-takeover clauses. Additionally, shorts will be less secure with the fact that a sudden offer could emerge at any time.

The rules seem to suggest that any offer and possible activation of LAT shares would require a general meeting to be called, meaning that it's feasible that a bid could in theory come before June 2024.

We will probably know more after tomorrow.

bamboo2
04/3/2024
07:34
Thanks Pinkfish; I have no position here but remain attentive.
brucie5
03/3/2024
16:24
Brucie, I don't know much just what I read and then engage brain a little.

I'm thinking the BoD changes are partly to defend against a low ball offer.
An offer declined by insiders on the BoD is open to question.
Put more outsiders on the BoD who then decline an offer and it's a different matter.
Pure speculation on my part.

Haven't checked the BoD composition recently but makes sense for at least someone from BioMerieux to be on there. They need to make space for more outside oversight and it could be no bad thing if someone decides to take advantage of lack of market love currently or invest like BioM and have a place on the BoD.

A hard test for PI's holding through this. Just hope people have appropriate position sizes and not over their heads as the stress isn't worth it.

Just as there has been a long drawn out decline, somewhere in the future is probably a long drawn out incline back up if not taken out first.

There's also the question of what the workers want. A company line ONT must be very dependent on many clever folk. An acquirer that isn't accepted can find themselves losing the very people that make the tech what it is.

Good luck with your holdings.

As for IPO, had a bad feeling about the CEO a while back so did reduce holding. Was a good decision. It needs change. Various posts questioning the upper levels as gave a bad vibe with crowing about past performances early on. Something lacking and when I get that vibe about management, so far, it hasn't been wrong to act upon it but should have done so sooner in the case of IPO, left it a bit late. I think Sanghera is solid and this is his baby - just my vibe, not scientific.

p1nkfish
03/3/2024
14:46
Pinkfish, I'm impressed by your knowledge. It can be surprising how stories change though, with either the right or wrong news. I don't think at these levels there's much optimism priced in. My concern is as ever, for a takeout, and an all too easy short term win for IPO. They don't have the best record I seem to remember. Ont is their crown jewel.
brucie5
03/3/2024
12:46
Same market in DNA sequencing but different offerings and strategies. ONT more or less portability and real-time sequencing, Pac Bio more focussed on long-read applications. ONT more towards pathogen detection and environmental/field research, Pac Bio towards research and clinical. A bit in parallel to each other but will probably collide sometime.

The whole lot under the cosh. Judging UK tech by ONT makes no sense as it's not alone and there are major dependencies on management. Look at IPO too, enough said.

Changing BoD composition at ONT may happen and help oversight - who knows.

A need to offer a compelling reason to buy the shares, outside of the tech and fascination with that, they haven't. We are in a time of show me the money and cash burn is out of favour - imho, dyor etc. Talk of target market size and impact is ignored.

Fantastic company and capabilities otherwise.

p1nkfish
03/3/2024
11:38
Question for the experts here - is Pacific Biosciences of California (Nasdaq) in the same field as this was a go go stock for ARK ETF and is literally being hammered and I wonder if there is a broader industry issue going on. Happy to be corrected if anyone can confirm...
takeiteasy
03/3/2024
11:35
But back to the share in question. If we can't retain the likes of IPO, we really are shafted as a global technology power. Successful companies like this are of course front loaded with huge costs to BE. The trick is, to keep hold of them when that initial period ends. We seem unable to do that under present circs, where LSE is becoming rapidly sidelined.
brucie5
03/3/2024
11:29
Pinkfish, I hope you're right, but part of the problem is that since Brexit the most promising companies in UK Plc are to be had for peanuts. Added to which, all too little of our own pension savings go into our own, reminiscent of JRM's cautionary note to his own clients about steering clear of UK equities on account of expected turbulence. You could hardly make it up.
brucie5
02/3/2024
15:16
I know people looking to invest heavily in the UK above other places you might expect them to be looking to place capital.
p1nkfish
29/2/2024
19:38
That's a lot of senior director changes to take in one go, hopefully replaced by PLC grade quality. More info would be helpful to avoid assuming the worst. These are the guys quite actively buying and selling if memory serves, so presumably pleased with their ride in a uni spin-out? Not overly concerned with two. I would expect the company to be mature enough to cope with the third (CTO) leaving. I wonder if 2.5 yrs is a minimum period they had to stay post IPO. Overall, feels a bit amateurish, but hopefully brings in decent quality. Their products are used almost universally in conversations I have with the market and tech all very highly regarded.
32v31today
29/2/2024
09:59
Ironically i plucked a pound out of the air when I was mulling this over - as hopefully a finger in the air guesstimate at some sort of bottom.

This must be proving so expensive for holders like Edinburgh Worldwide IT and IP group etc...and a one way short for the hedge funds until the management restore trust and confidence again ...dyor and no advice...

takeiteasy
29/2/2024
09:53
This appears to be in relentless decline. Never mind the prospects and the cash runway, is it inconceivable that it could be run down to the £1 level? It's now well passed the 25% of peak reached in 2021.
brucie5
26/2/2024
18:04
Interesting, unless I imagined it, 80M+ shares changed hands in IPO today around 3.35pm. IF IT HAPPENED and isn't just a mistake in reporting, it matters to ONT as IPO hold a wadge.
p1nkfish
26/2/2024
08:40
3-hour genome sequencing and targeted analysis to rapidly assess genetic risk

The main objection to using this technique in clinical care is the cost, although costs of flowcells are falling.



ABSTRACT [full text, use link]

Purpose

Rapid genetic testing in the critical care setting may guide diagnostic evaluation, direct therapies, and help families and care providers make informed decisions about goals of care. We tested whether a simplified DNA extraction and library preparation process would enable us to perform ultra-rapid assessment of genetic risk for a Mendelian condition, based on information from an affected sibling, using long-read genome sequencing and targeted analysis.

Methods

Following extraction of DNA from cord blood and rapid library preparation, genome sequencing was performed on an Oxford Nanopore PromethION. FASTQ files were generated from original sequencing data in near real-time and aligned to a reference genome. Variant calling and analysis were performed at timed intervals.

Results

We optimized the DNA extraction and library preparation methods to create sufficient library for sequencing from 500 μL of blood. Real-time, targeted analysis was performed to determine that the newborn was neither affected nor a heterozygote for variants underlying a Mendelian condition. Phasing of the target region and prior knowledge of the affected haplotypes supported our interpretation despite a low level of coverage at 3 hours of life.

Conclusion

This proof-of-concept experiment demonstrates how prior knowledge of haplotype structure or familial variants can be used to rapidly evaluate an individual at risk for a genetic disease. While ultra-rapid sequencing remains both complex and cost prohibitive, our method is more easily automated than prior approaches and uses smaller volumes of blood, thus may be more easily adopted for future studies of ultra-rapid genome sequencing in the clinical setting.

bamboo2
17/2/2024
13:58
The definitive article is the press release from Cyclomics.



I am unsure how this new deal will affect the existing agreement between Cyclomics and ONT, suffice to say that since the CyclomicsSeq workflow is effectively a partnership and the sequencing element relies/depends on ONT sequencing, the outcome will likely be very positive.

I wouldn't be surprised to see the new entity owning ONT stock and given the two co's have extensive agreements with Nvidia, we could even see Nvidia taking a stake.

The original agreement dated 16/3/2023 is noted here,

bamboo2
16/2/2024
21:43
There's clearly a very complex back story. It's so complex that I have to take it at face value for now.

Both companies have agreed to work on the drafting of a definitive agreement, and the combined company will advance the entry into the cancer monitoring market and gain access to integrating whole genome data into GEDiCube’s AI-ML platform

bamboo2
16/2/2024
21:25
Cyclomics news could be good for ONT.
bamboo2
02/2/2024
18:21
GIC Private Limited, Singapore.
Singapore Sovereign Wealth Fund.

Reducing from 4.2447% to 3.976561%

Post 1 amended.

bamboo2
02/2/2024
15:06
On the surface, the story appears to be pretty much the same in 2023. Oxford Nanopore expects a 39% increase in underlying revenue growth and a similar 25%-75% split in machines versus consumables sales. So, you might be a wee bit surprised to learn that Oxford Nanopore stock is down more than 20% since CEO Gordon Sanghera released preliminary numbers back on January 9 and geeked out about genomic sequencing science for 37 minutes. We know because we listened to the whole thing.

There are a few reasons why Oxford Nanopore stock took a hit – none of which we think affects the company’s long-term prospects...

Nanalyse view point...

bamboo2
Chat Pages: Latest  121  120  119  118  117  116  115  114  113  112  111  110  Older

Your Recent History

Delayed Upgrade Clock